PPLPHARMA Piramal Pharma Q2 FY25 results (Jul–Sep 2024) and concall
Piramal Pharma delivered a strong Q2 FY25, characterized by double-digit revenue growth and margin expansion, particularly in the CDMO segment which is benefiting from on-patent commercial manufacturing. The company is aggressively investing in differentiated capabilities like sterile fill-finish and ADCs to capture shifting demand in the global pharma supply chain. While facing headwinds from high effective tax rates and uneven biotech funding, management remains confident in its long-term roadmap to reach $2 billion in revenue by FY30.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 2,242 |
| EBITDA | 342 |
| Net profit | 23 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
